Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA as First-Line Treatment for Adult Patients With Advanced RCC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Merck (MRK) Announces European Commission Approves KEYTRUDA Plus LENVIMA as First-Line Treatment for Adult Patients With Advanced RCC

Merck (MRK) Announces KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma

November 30, 2021 6:45 AM EST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Mercks anti-PD-1 therapy, has been approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line treatment of patients with radically unresectable, advanced or recurrent esophageal carcinoma in combination with chemotherapy (5-fluorouracil [5-FU] plus cisplatin) based on data from the Phase 3 KEYNOTE-590 trial.

In Japan,... More